ABSTRACT
Monoclonal gammopathy of undetermined significance (MGUS) is commonly diagnosed in outpatients being worked up for an array of clinical concerns. It carries a risk of progression to myeloma and other lymphoproliferative disorders that, albeit low (1% per year), warrants regular follow-up. Patients with MGUS can be risk-stratified on the basis of the amount and type of their monoclonal protein as well as whether they have an abnormal light-chain ratio. Here, we provide a guide to the diagnosis, workup, and management of MGUS.
Footnotes
Dr. Valent has disclosed teaching and speaking for Amgen, Celgene, and Takeda.
- Copyright © 2019 The Cleveland Clinic Foundation. All Rights Reserved.
- Jack Khouri, MD⇑
- ADDRESS:
Jack Khouri, MD, Department of Hematology and Medical Oncology, Taussig Cancer Institute, CA-60, Cleveland Clinic, 10201 Carnegie Avenue, Cleveland, OH 44195; khourij{at}ccf.org
- Christy Samaras, DO
- Jason Valent, MD
- Alex Mejia Garcia, MD
- Beth Faiman, PhD, CNP
- Saveta Mathur, CNP
- Kim Hamilton, CNP
- Megan Nakashima, MD
- Matt Kalaycio, MD
ABSTRACT
Monoclonal gammopathy of undetermined significance (MGUS) is commonly diagnosed in outpatients being worked up for an array of clinical concerns. It carries a risk of progression to myeloma and other lymphoproliferative disorders that, albeit low (1% per year), warrants regular follow-up. Patients with MGUS can be risk-stratified on the basis of the amount and type of their monoclonal protein as well as whether they have an abnormal light-chain ratio. Here, we provide a guide to the diagnosis, workup, and management of MGUS.
Footnotes
Dr. Valent has disclosed teaching and speaking for Amgen, Celgene, and Takeda.
- Copyright © 2019 The Cleveland Clinic Foundation. All Rights Reserved.
